AEZS News 1.33 08/20/2014 04:28:04 Aeterna Zentaris (AEZS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 1.33 $AEZS

4 Stocks Under $10 to Trade Now
at The Street - Fri Aug 15, 5:00AM CDT
Stocks making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst.

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
PR Newswire - Thu Aug 07, 3:30PM CDT
All amounts are in US dollars

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
CNW Group - Wed Aug 06, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Canaccord Genuity 34th Annual Global Growth Conference on Wednesday, August 13, 2014, at 1pm (Eastern), in the Melbourne Room of the Intercontinental Hotel in Boston.

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
PR Newswire - Tue Aug 05, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND" . Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel® a non-patch transdermal U.S. Food & Drug Administration ("FDA" approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency ("AGHD" , for which a New Drug Application ("NDA" is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA" date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.

Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:

Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.

Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada.

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 288

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 29

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 37

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched Over Designer Brands Inc. Stock Concerns

Updated Category News Views 169

Insights into Designer Brands Inc.'s Ongoing Investigation In recent developments, Pomerantz LLP has begun an investigation focusing on Designer Brands Inc. and its operations within the retail space. Designer Brands Inc. is a prominent name in the footwear and apparel industry, known for its brand offerings and retail presence. Investors should pay close attention to...

Continue Reading
TECNO Unveils Innovative AI-Powered MEGAPAD Pro Experience

Updated Category News Views 338

Introducing the TECNO MEGAPAD Pro: A Game Changer in Tablet Technology TECNO has taken a monumental step in the tech world with the launch of the MEGAPAD Pro, an innovative tablet designed as the "Essential AI Tablet." This groundbreaking device boasts a remarkable 12-inch 2K eye-care display that prioritizes user health without compromising on functionality. Equipped...

Continue Reading
Vestis Corporation Faces Legal Scrutiny Amid Investor Concerns

Updated Category News Views 194

Vestis Corporation Under Investigation for Securities Violations Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is reaching out to investors involved with Vestis Corporation regarding potential legal claims. Investors who have faced significant financial losses while holding Vestis securities are encouraged to connect with the...

Continue Reading
AerCap's Milestone: First Boeing 777-300ERSF for Fly Meta

Updated Category News Views 239

AerCap's Milestone Delivery of the Boeing 777-300ERSF AerCap Holdings N.V. (NYSE: AER) has recently marked a significant milestone in aviation leasing by successfully delivering the first Boeing 777-300ERSF converted aircraft to Fly Meta Leasing Co., Ltd. This notable event represents not just a transaction, but a transformative step in the cargo aviation sector. The New...

Continue Reading
Exploring Aitech's Groundbreaking AI-Enabled Picosatellite Technology

Updated Category News Views 436

Aitech Introduces a Revolutionary AI-Enabled Picosatellite Platform The IQSat brings advanced AI capabilities in a cost-effective platform for low Earth orbit missions, enabling previously unreachable actionable data and insights. At a recent event, Aitech, a prominent provider of robust embedded systems tailored for military and aerospace applications, unveiled its...

Continue Reading